On October 14, 2026, Armed Cell Therapeutics BV (“Armed Cell”) announced that it acquired a portfolio of preclinical CAR-T assets from Lakefront Biotherapeutics NV (“Lakefront”), formerly Galapagos NV. The two lead programs focus on non-Hodgkin lymphoma and small cell lung cancer. Under the agreement, Lakefront receives an upfront payment and…
